Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neose Technologies has received a milestone payment from Novo Nordisk under a license agreement for the use of Neose's GlycoPEGylation technology to develop a next-generation version of recombinant Factor VIII.
Subscribe to our email newsletter
Novo Nordisk continues to fully fund Neose’s development work for Factor VIII. The company is also working with Novo Nordisk under separate license agreements to develop long-acting, GlycoPEGylated versions of recombinant Factors VIIa and IX.
George Vergis, president and CEO of Neose, said: “Our collaboration with Novo Nordisk on recombinant Factors VIIa, VIII and IX continues to show great promise, and we are excited about the benefits our GlycoPEGylation technology may provide to Novo in broadening their hemostasis product portfolio.”